All News
The future of lupus treatment is oral therapies?
There has been an explosion of trials in SLE, including nonrenal and glomerulonephritis studies.
@Janetbirdope
https://t.co/IQ9bxbTSV4 https://t.co/jVYOphxpAE
Links:
Dr. John Cush RheumNow ( View Tweet)
In an early SpA (DESIR) cohort, the occurrence of a first pregnancy did not seem to increase the number of imaging abnormalities of the SIJ. Overall no significant changes in radiographic and MRI imaging abnormalities of the SIJ, Molto A, Abst#POS0303, #EULAR2023 @RheumNow
Dr. Antoni Chan synovialjoints ( View Tweet)
Supervised 12 weeks High-intensity interval training program
Improves Vo2 peak in IA patients
But does not improve pain or fatigue
It is disappointing but it is also a small study w/ n=30 pts in each group.
It is unclear if the type of exercise has an impact on outcome https://t.co/Plk7sflrh5
Aurelie Najm AurelieRheumo ( View Tweet)
What happens when an AI-based symptom checker & an online self-referral tool play Rheumatologists?
They don't seem to do great yet!
600 new pts, outw/ 36% dvlpd IA
IA Sens 62% Spe 47%
Tool Sens 66% Spe 54%
More work needed to implement these in practice
#EULAR23 @Rheumnow
Aurelie Najm AurelieRheumo ( View Tweet)
RheumNow’s expanded coverage of the #EULAR2023 meeting is sponsored in part by Bristol Myers Squibb. All content is chosen by RheumNow and its faculty.
Dr. John Cush RheumNow ( View Tweet)
RheumNow Eular 2023 Daily Recap Series https://t.co/ZJd3mSBcau
Dr. John Cush RheumNow ( View Tweet)
AOSD: Young vs. Elderly Onset
AOSDis an autoinflammatory condition characterized by fevers, arthritis, and rash. It is considered an orphan disease because of its low prevalence - it is reported anywhere between 16 to 40 per ten million.
https://t.co/PPI1fvwLAf https://t.co/qMXMsbpwl3
Links:
Dr. John Cush RheumNow ( View Tweet)
Top Influencers of #EULAR2023 👉 @eular_org @EMEUNET @RheumNow @ARD_BMJ @drdavidliew @Janetbirdope https://t.co/uUJM6tW824 via @symplur
Alina DIMA drALINAdima ( View Tweet)
Wasn’t following the SLE stuff #EULAR2023 but heard a lot of talk about both telitacicept & CAR-T, including meeting highlights by Christian Dejaco.
Both look pretty exciting - the longer the sustained remission with CAR-T, the more it looks like maybe the real deal @RheumNow https://t.co/oKzb8ojTcz
David Liew drdavidliew ( View Tweet)
#EULAR2023 Clinical Highlights. Osteoarthritis. OP0071 Single centre Phase 2 RCT showed Denosumab halted erosion in Erosive OA at 24 weeks treatment, and the treatment effect enhances after 48 weeks vs PBO @RheumNow https://t.co/YWFUg3cp7P
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Tune it at 1pm EST for RheumNow's daily #EULAR23 recaps. You can find us live on YouTube, Twitter and LinkedIn. https://t.co/i8rm5t8mFS
Dr. John Cush RheumNow ( View Tweet)
RheumNow’s expanded coverage of the #EULAR2023 annual meeting is sponsored in part by Bristol Myers Squibb. All content is chosen by RheumNow and its faculty.
Dr. John Cush RheumNow ( View Tweet)
Depositions of crystals in coronary arteries were associated with MACE @rheumnow #EULAR2023 https://t.co/VHxtsB7ZsA
Bella Mehta bella_mehta ( View Tweet)
Adherence to TNFi follows different trajectories
Cluster 1: “moderate then high” 51%
Cluster 2: “moderate then low” 20%
Cluster 3: “low adherence, to discontinuation” 18%
Cluster 4: “low then high adherence” 11%
Most demographic & clinical features CAN NOT predict trajectory! https://t.co/4wLg6b70Kl
Aurelie Najm AurelieRheumo ( View Tweet)
@eular_org recommendations session #EULAR2023 - and the first recommendation is one I’m so glad is up front:
Adult Onset Still’s Disease (AOSD) and Systemic JIA (sJIA) are the same disease.
If anything, it’s the really young sJIA (<18 months old) which is different @RheumNow https://t.co/OCDeeNtNoR
David Liew drdavidliew ( View Tweet)
@eular_org recommendation for AOSD/sJIA:
An IL-1 or IL-6 inhibitor should be initiated as early as possible when the diagnosis is established
#EULAR2023 @RheumNow https://t.co/xNUdpGDxb9
David Liew drdavidliew ( View Tweet)
#EULAR2023 #POS1156 Previous case series reported ~9% de novo nephritis in #SLE pts treated with belimumab for non-renal lupus. Post-hoc analysis of 5 BEL Non-LN RCTs showed 8% had de novo LN. Risk increased in Asians but lowered with low dose BEL or s/c form @RheumNow https://t.co/GqAr3tppWh
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
One new overarching principle for @eular_org PsA recommendations:
“The choice of treatment should take account of safety considerations regarding individual MoA to optimize the benefit-risk profile”
Wonder what triggered that
#EULAR2023 #oralsurveillance @RheumNow https://t.co/19BfJQz4Za
David Liew drdavidliew ( View Tweet)
The incidence of MACEs at 8 years is low in AS patients treated with NSAIDs. Study of 22929 patients, NSAIDs (SHR: 0.40 [0.32-0.49], p<0.001) and anti-TNFs (SHR: 0.61 [0.47-0.81], p<0.001) associated with a lower risk of MACE, Fakih O, Abst#POS0301, #EULAR2023 @RheumNow https://t.co/i5GZMcJwyO
Dr. Antoni Chan synovialjoints ( View Tweet)
New 2023 @eular_org SLE recommendations
Key changes, in response to evidence:
- more caution re: steroids
- biologics earlier
- combo therapy (BEL or CNI/VCS) considered for lupus nephritis
#EULAR2023 @RheumNow https://t.co/J3Lp8owRyT
David Liew drdavidliew ( View Tweet)